|
Name |
Neobulgarone G
|
| Molecular Formula | C32H24Cl2O9 | |
| IUPAC Name* |
(10S)-4-chloro-10-[(9S)-1-chloro-2,4-dihydroxy-7-(hydroxymethyl)-5-methoxy-10-oxo-9H-anthracen-9-yl]-1,3-dihydroxy-8-methoxy-6-methyl-10H-anthracen-9-one
|
|
| SMILES |
CC1=CC2=C(C(=C1)OC)C(=O)C3=C([C@H]2[C@H]4C5=C(C(=CC(=C5)CO)OC)C(=O)C6=C4C(=C(C=C6O)O)Cl)C(=C(C=C3O)O)Cl
|
|
| InChI |
InChI=1S/C32H24Cl2O9/c1-11-4-13-21(19(5-11)42-2)31(40)25-15(36)8-17(38)29(33)27(25)23(13)24-14-6-12(10-35)7-20(43-3)22(14)32(41)26-16(37)9-18(39)30(34)28(24)26/h4-9,23-24,35-39H,10H2,1-3H3/t23-,24-/m1/s1
|
|
| InChIKey |
MQMWBFUKNWTRJV-DNQXCXABSA-N
|
|
| Synonyms |
Neobulgarone G; CHEMBL1643636
|
|
| CAS | NA | |
| PubChem CID | 53317590 | |
| ChEMBL ID | CHEMBL1643636 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 623.4 | ALogp: | 6.4 |
| HBD: | 5 | HBA: | 9 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 154.0 | Aromatic Rings: | 6 |
| Heavy Atoms: | 43 | QED Weighted: | 0.189 |
| Caco-2 Permeability: | -5.734 | MDCK Permeability: | 0.00000779 |
| Pgp-inhibitor: | 0.137 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.97 | 20% Bioavailability (F20%): | 0.004 |
| 30% Bioavailability (F30%): | 0.999 |
| Blood-Brain-Barrier Penetration (BBB): | 0 | Plasma Protein Binding (PPB): | 95.17% |
| Volume Distribution (VD): | 0.292 | Fu: | 12.73% |
| CYP1A2-inhibitor: | 0.702 | CYP1A2-substrate: | 0.555 |
| CYP2C19-inhibitor: | 0.175 | CYP2C19-substrate: | 0.051 |
| CYP2C9-inhibitor: | 0.607 | CYP2C9-substrate: | 0.801 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.279 |
| CYP3A4-inhibitor: | 0.013 | CYP3A4-substrate: | 0.056 |
| Clearance (CL): | 4.681 | Half-life (T1/2): | 0.364 |
| hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.033 |
| Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.18 |
| Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.964 |
| Skin Sensitization: | 0.911 | Carcinogencity: | 0.022 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.926 |
| Respiratory Toxicity: | 0.094 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002039 | ![]() |
0.878 | D09LBS | ![]() |
0.293 | ||
| ENC005319 | ![]() |
0.443 | D0Z2LG | ![]() |
0.293 | ||
| ENC002029 | ![]() |
0.443 | D0AZ8C | ![]() |
0.265 | ||
| ENC002767 | ![]() |
0.432 | D06GCK | ![]() |
0.257 | ||
| ENC000947 | ![]() |
0.411 | D0C9XJ | ![]() |
0.246 | ||
| ENC000911 | ![]() |
0.411 | D07VLY | ![]() |
0.246 | ||
| ENC002766 | ![]() |
0.408 | D07MGA | ![]() |
0.245 | ||
| ENC006027 | ![]() |
0.398 | D01XWG | ![]() |
0.236 | ||
| ENC005390 | ![]() |
0.394 | D0D4HN | ![]() |
0.232 | ||
| ENC002596 | ![]() |
0.394 | D05HSC | ![]() |
0.231 | ||